4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
MedKoo(授权代理)
主营:主营:抗癌化学试剂和激酶抑制剂
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > Other_reagents > MedKoo Biosciences/KP372-1/401520/2g
商品详细MedKoo Biosciences/KP372-1/401520/2g
MedKoo Biosciences/KP372-1/401520/2g
MedKoo Biosciences/KP372-1/401520/2g
商品编号: 401520-2g
品牌: MedKoo
市场价: ¥0.00
美元价: 0.00
产地: 美国(厂家直采)
公司:
产品分类: 其他试剂
公司分类: Other_reagents
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍
KP372-1 is a synthetic small molecule AKT inhibitor. KP372-1 is consisted of two isomers: KP372-1 A and KP372-1B. KP372-1 showed activities to block signalling downstream of Akt in thyroid tumour cells, leading to inhibition of cell proliferation and increased apoptosis. KP372-1 has also been shown to suppress cell proliferation and induce apoptosis in gliobastoma.

MedKoo Cat#: 401520
Name: KP372-1
CAS#: 329710-24-9
Chemical Formula: C10H4N6O
Exact Mass: 224.04466
Molecular Weight: 224.17836
Elemental Analysis: C, 53.58; H, 1.80; N, 37.49; O, 7.14


Synonym: KP3721, KP 3721, KP-3721

IUPAC/Chemical Name: KP372-1A: 10H-indeno[2,1-e]tetrazolo[1,5-b][1,2,4]triazin-10-one

InChi Key: SSNMLKNJEUSPDY-UHFFFAOYSA-N

InChi Code: InChI=1S/C10H4N6O/c17-9-6-4-2-1-3-5(6)7-8(9)11-10-12-14-15-16(10)13-7/h1-4H

SMILES Code: O=C(C1=NC2=NN=NN2N=C13)C4=C3C=CC=C4


Technical Data

Appearance:
Solid powder

Purity:
>98%

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>5 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

 
 
 
 


References

1: Liu B, Wu JM, Li J, Liu JJ, Li WW, Li CY, Xu HL, Bao JK. Polygonatum cyrtonema lectin induces murine fibrosarcoma L929 cell apoptosis and autophagy via blocking Ras-Raf and PI3K-Akt signaling pathways. Biochimie. 2010 Dec;92(12):1934-8. Epub 2010 Aug 14. PubMed PMID: 20713122.

2: Shao H, Yi XM, Wells A. Epidermal growth factor protects fibroblasts from apoptosis via PI3 kinase and Rac signaling pathways. Wound Repair Regen. 2008 Jul-Aug;16(4):551-8. PubMed PMID: 18638274; PubMed Central PMCID: PMC2547354.

3: Xi RG, Huang J, Li D, Wang XB, Wu LJ. Roles of PI3-K/Akt pathways in nanoparticle realgar powders-induced apoptosis in U937 cells. Acta Pharmacol Sin. 2008 Mar;29(3):355-63. PubMed PMID: 18298901.

4: Li D, Cui Q, Chen SG, Wu LJ, Tashiro S, Onodera S, Ikejima T. Inactivation of ras and changes of mitochondrial membrane potential contribute to oridonin-induced autophagy in a431 cells. J Pharmacol Sci. 2007 Sep;105(1):22-33. PubMed PMID: 17895587.

5: Zeng Z, Samudio IJ, Zhang W, Estrov Z, Pelicano H, Harris D, Frolova O, Hail N Jr, Chen W, Kornblau SM, Huang P, Lu Y, Mills GB, Andreeff M, Konopleva M. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res. 2006 Apr 1;66(7):3737-46. PubMed PMID: 16585200.

6: Koul D, Shen R, Bergh S, Sheng X, Shishodia S, Lafortune TA, Lu Y, de Groot JF, Mills GB, Yung WK. Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Mol Cancer Ther. 2006 Mar;5(3):637-44. PubMed PMID: 16546978.

7: Mandal M, Younes M, Swan EA, Jasser SA, Doan D, Yigitbasi O, McMurphey A, Ludwick J, El-Naggar AK, Bucana C, Mills GB, Myers JN. The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell carcinoma of the head and neck. Oral Oncol. 2006 Apr;42(4):430-9. Epub 2006 Jan 27. PubMed PMID: 16442835; PubMed Central PMCID: PMC1414640.

8: Mandal M, Kim S, Younes MN, Jasser SA, El-Naggar AK, Mills GB, Myers JN. The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. Br J Cancer. 2005 May 23;92(10):1899-905. PubMed PMID: 15870708; PubMed Central PMCID: PMC2361761.

品牌介绍
MedKoo 美帝药库公司以药物化学合成技术为核心,密切结合全球抗癌新药研发领域中的新技术、新理论、新趋势和新的发展方向,不断推出抗癌化合物新品种。 。 美帝药库MedKoo将在中国建立药物化学合成生产基地和多个现代化药物化合物存储仓库。 美帝药库的药物化合物来源于以下几个渠道:自主合成、委托化学合成、合作伙伴、和从国内外市场上选购。 MedKoo美帝药库的抗癌分子库 MedKoo的目标是打造全球规模最大、品种最多、类别最全和质量最好的小分子抗癌化合物库。MedKoo的抗癌药库将由下列5个分子库组成: (1)上市抗癌药库:该库将含有大约100个全球已批准上市的小分子抗癌化合物; (2)抗癌候选药物库:该分子库含有大约400个世界各国正在临床研究中抗癌小分子候选药物; (3)同系抗癌分子库:该分子库将含有多个化学结构类似或抗癌机制类似的分子包; (4)抗癌分子预制模块库:该库主要含有用于组建抗癌目标分子的分子模块包; (5)同位素标记抗癌分子库。